ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

BRD9-SMAD2/3 Orchestrates Stemness and Tumorigenesis in Pancreatic Ductal Adenocarcinoma

Feng, Yuliang; Cai, Liuyang; Pook, Martin; Liu, Feng; Chang, Chao-Hui; Mouti, Mai Abdel; Nibhani, Reshma; Militi, Stefania; Dunford, James; Philpott, Martin; Fan, Yanbo; Fan, Guo-Chang; Liu, Qi; Qi, Jun; Wang, Cheng; Hong, Wanzi; Morgan, Hannah; Wang, Mingyang; Sadayappan, Sakthivel; Jegga, Anil G.; Oppermann, Udo; Wang, Yigang*; Huang, Wei*; Jiang, Lei*; Pauklin, Siim*广东省人民医院; 广东省心血管病研究所; 南方医科大学
Gastroenterology2024-1DOI: 10.1053/j.gastro.2023.09.021
6阅读
引用收藏
分享

摘要

BACKGROUND & AIMS: The dismal prognosis of pancreatic ductal adenocarcinoma (PDAC) is linked to the presence of pancreatic cancer stem-like cells (CSCs) that respond poorly to current chemotherapy regimens. The epigenetic mechanisms regulating CSCs are currently insuffi- ciently understood, which hampers the development of novel strategies for eliminating CSCs. METHODS: By small molecule compound screening targeting 142 epigenetic enzymes, we identified that bromodomain-containing protein BRD9, a component of the BAF histone remodeling complex, is a key chromatin regulator to orchestrate the stemness of pancreatic CSCs via cooperating with the TGFb/Activin-SMAD2/3 signaling pathway. RESULTS: Inhibition and genetic ablation of BRD9 block the self-renewal, cell cycle entry into G0 phase and invasiveness of CSCs, and improve the sensitivity of CSCs to gemcitabine treatment. In addition, pharmacological in-hibition of BRD9 significantly reduced the tumorigenesis in patient-derived xenografts mouse models and eliminated CSCs in tumors from pancreatic cancer patients. Mechanis-tically, inhibition of BRD9 disrupts enhancer-promoter looping and transcription of stemness genes in CSCs. CONCLUSIONS: Collectively, the data suggest BRD9 as a novel therapeutic target for PDAC treatment via modulation of CSC stemness.

学科与关键词

关键词
Cancer Stem CellsCancer TherapyEpigeneticsPancreatic CancerTGFb/Activin-SMAD2/3
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Gastroenterology
发表日期
2024-01
卷期
第 166 卷, 第 1 期
DOI
10.1053/j.gastro.2023.09.021
语言
ENGLISH
成果收录
SCIE
资助标注
Cancer Research UK Career Development Fellowship [C59392/A25064]; Pancreatic Cancer UK [2018RIF_03]; National Natural Science Foundation of China of China [81800262]; Natural Science Foundation of Guangdong Province [2018A030313029]; Science and Technology Planning Project of Guangzhou [201903010005]; National Institutes of Health [R01 AR078001, R01 HL130356, R01 HL105826, R38 HL155775, R01 HL143490, R01 HL163148, R01 HL157456]; Clarendon Fund; St Edmund Hall Scholarship [SFF1920_CB_MSD_759707]; Kennedy Trust for Rheumatology Research (Daphne Jackson Fellowship)

作者

  • F

    Feng, Yuliang (第一作者)

  • C

    Cai, Liuyang

查看全部 25 位作者收起作者
  • P

    Pook, Martin

  • L

    Liu, Feng

  • C

    Chang, Chao-Hui

  • M

    Mouti, Mai Abdel

  • N

    Nibhani, Reshma

  • M

    Militi, Stefania

  • D

    Dunford, James

  • P

    Philpott, Martin

  • F

    Fan, Yanbo

  • F

    Fan, Guo-Chang

  • L

    Liu, Qi

  • Q

    Qi, Jun

  • W

    Wang, Cheng

  • H

    Hong, Wanzi

  • M

    Morgan, Hannah

  • W

    Wang, Mingyang

  • S

    Sadayappan, Sakthivel

  • J

    Jegga, Anil G.

  • O

    Oppermann, Udo

  • W

    Wang, Yigang (通讯)

  • H

    Huang, Wei (通讯)

  • J

    Jiang, Lei (通讯)

    guangdong cardiovasc inst · guangdong prov peoples hosp · southern med univ

  • P

    Pauklin, Siim (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417